An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2 Meeting Abstract
| Authors: | Lee, J. Y.; Makker, V.; Oaknin, A.; Oh, D. Y.; Anoka, C.; Jung, L.; Simoes, J.; Puvvada, S. D.; Meric-Bernstam, F. |
| Abstract Title: | An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2 |
| Meeting Title: | ESMO Asia Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2024 Dec 6-8 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-12-01 |
| Start Page: | S1553 |
| Language: | English |
| ACCESSION: | WOS:001388888700004 |
| DOI: | 10.1016/j.annonc.2024.10.421 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 400TiP -- Source: Wos |
